Compare

Xenon Pharmaceuticals/$XENE

1D1W1M3M6MYTD1Y5YMAX

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Ticker
$XENE
Sector
Health
Primary listing
NASDAQ
Employees
364
Headquarters
Burnaby, Canada
Website
www.xenon-pharma.com

XENE Metrics

BasicAdvanced
$3.5B
-
-$4.73
0.62
-

What the Analysts think about XENE

Analyst ratings (Buy, Hold, Sell) for Xenon Pharmaceuticals stock.
Analyst projections of the future price of Xenon Pharmaceuticals stock.

Bulls say / Bears say

Phase 3 X-TOLE2 met its primary endpoint: monthly focal-seizure frequency fell by a median 53.2% at 25 mg and 34.5% at 15 mg, versus 10.4% on placebo. The placebo-adjusted result at 25 mg was 42.7%, strengthening the case for azetukalner in focal seizures. (Xenon Pharmaceuticals)
Xenon submitted its first azetukalner NDA to the FDA for focal seizures, backed by two controlled studies. This moves its lead drug into formal review and gives investors a clear regulatory catalyst. (Nasdaq)
Xenon reported $1.245 billion in cash, cash equivalents and marketable securities at the end of June 2026, with funding expected to last into 2029. That gives it room to support the planned launch and advance other programmes without an immediate need to raise capital. (SEC)
Xenon paused new enrolment in its Phase 3 depression and bipolar-depression trials after neuropsychiatric side effects emerged. These events had not appeared in the earlier Phase 2 depression study, putting the drug’s potential beyond epilepsy in doubt. (Reuters)
In X-TOLE2, adverse events led 14.5% of patients on the 25 mg dose to stop treatment, compared with 4.8% on 15 mg and 3.2% on placebo. This dose-related tolerability trade-off could limit the usable dose or complicate the product’s eventual label. (Yahoo Finance)
Xenon reported a $110.7 million net loss for Q2 2026, while research and development spending rose to $99.2 million from $75.0 million a year earlier. It must turn its costly development programme into an approved product and commercial revenue to sustain the investment case. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 15 Oct 2026.

XENE Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

XENE Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

XENE News

AllArticlesVideos

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

Newsfile Corp1 month ago

Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review

MarketBeat1 month ago

XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law

Business Wire1 month ago

Funds containing XENE

Funds
Fund name
Fund size
$XENE weighting
iShares Healthcare Innovation£DRDR
$1.3B0.34%
iShares Healthcare Innovation€2B78
$1.2B0.34%
iShares Healthcare Innovation$HEAL
$1.3B0.34%
iShares Ageing Population$AGED
$953M0.31%
iShares Ageing Population£AGES
$953M0.31%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.